Prevalence of Duffy null and its impact on hydroxyurea in young children with sickle cell disease in the United States.
Fathia OladipupoJoseph R StanekJoseph WaldenJennifer YoungMelissa J RoseKathleen NicolAnthony VillellaSusan E CrearyPublished in: Pediatric blood & cancer (2024)
Consistent with studies showing a high prevalence of the Duffy null phenotype among healthy Black Americans, this retrospective study found that Duffy null was present in >75% of a young and contemporary cohort of children with sickle cell disease (SCD) in the United States. Despite the potential for this phenotype to impact absolute neutrophil counts, hydroxyurea (HU) dosing, and outcomes, it was not associated with being prescribed a lower HU dose or having increased acute SCD visits early in the HU treatment course. Future studies are needed to confirm these findings in older children with SCD.